Form 4: Nautilus Biotechnology Chief Scientist Parag Mallick Increases Stake in Company

Parag Mallick, Chief Scientist at Nautilus Biotechnology, recently purchased additional shares of the company's common stock, increasing his total holdings.

Summary

• On May 8, 2025, Parag Mallick, the Chief Scientist of Nautilus Biotechnology, acquired 12,000 shares of common stock at a weighted average price of $0.7323.
• These shares were purchased in a price range of $0.7058 to $0.7520.
• Following this transaction, Mallick directly owns 20,491,892 shares.
• On May 12, 2025, Mallick acquired an additional 1,500 shares of common stock at a weighted average price of $0.7317.
• These shares were purchased in a price range of $0.7229 to $0.7334.
• Following this transaction, Mallick directly owns 20,493,392 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the scale of the purchases is relatively small in the context of Mallick's existing holdings.

Positives

• The Chief Scientist's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that those with the most knowledge of the company's prospects are optimistic about its future.

Stakeholder Impact

• The increased stake of a key executive could improve investor confidence.

Key Dates

Keywords

Nautilus Biotechnology, Parag Mallick, insider trading, share purchase, common stock, NAUT, Chief Scientist